Search for Clinical Trial Results

Prostatic Neoplasms, Castration-Resistant - 22 Studies Found
Status | Study |
Active, not recruiting |
Study Name: A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Date: 2015-10-29 Interventions:
|
Suspended |
Study Name: Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Date: 2015-12-07 Interventions:
|
Active, not recruiting |
Study Name: A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Date: 2014-06-11 Interventions: Drug: JNJ-56021927 Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single or |
Recruiting |
Study Name: IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen Condition: Prostatic Neoplasms, Castration-Resistant Date: 2017-01-09 Interventions:
|
Withdrawn |
Study Name: A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Date: 2016-09-15 Interventions:
|
Not yet recruiting |
Study Name: Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer ) Condition: Prostatic Neoplasms, Castration-Resistant Date: 2016-07-19 Interventions: Drug: Xofigo (Radium-223 dichloride, BAY88-8223 Xofigo is indicated for the treatment of patients with c |
Recruiting |
Study Name: Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases Condition: Prostatic Neoplasms, Castration-Resistant Date: 2016-06-14 Interventions: Drug: Radium-223 dichloride (Xofigo, BAY 88-8223) Xofigo treatment will be performed according to the pr |
Recruiting |
Study Name: Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany Condition: Prostatic Neoplasms, Castration-Resistant Date: 2015-05-19 Interventions: Drug: Radium-223-dichloride (Xofigo, BAY88-8223) according to Summary of Product Characteristics |
Recruiting |
Study Name: BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) Condition: Prostatic Neoplasms, Castration-Resistant Date: 2014-07-29 Interventions:
|
Not yet recruiting |
Study Name: A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer Condition:
Date: 2016-11-14 Interventions: |